Zobrazeno 1 - 10
of 223
pro vyhledávání: ''
Autor:
Angela Dispenzieri
Publikováno v:
American Journal of Hematology. 96:872-888
Disease overview POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endot
Autor:
Zeev Estrov, Nitin Jain, Elias Jabbour, Srdan Verstovsek, Guillermo Garcia-Manero, Sherry Pierce, Farhad Ravandi, Uday R. Popat, Marina Konopleva, Xuelin Huang, Naval Daver, Naveen Pemmaraju, Hagop M. Kantarjian, Xuemei Wang, Gautam Borthakur, Caitlin R. Rausch, Alessandra Ferrajoli, Tapan M. Kadia, Jan A. Burger, Rashmi Kanagal-Shamanna, Courtney D. DiNardo
Publikováno v:
American Journal of Hematology. 96:914-924
Background The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower-intensity regimens with clofarabine (n=11
Autor:
Gita Thanarajasingam, Asher Chanan-Khan, Prashant Kapoor, Angela Dispenzieri, Ronald S. Go, Wilson I. Gonsalves, Eli Muchtar, Morie A. Gertz, Allison C. Rosenthal, Thomas M. Habermann, Rebecca L. King, Jithma P. Abeykoon, David J. Inwards, Francis K. Buadi, Patricia T. Greipp, Vivek Roy, Sikander Ailawadhi, Robert A. Kyle, Grzegorz S. Nowakowski, Craig B. Reeder, David Dingli, Carrie A. Thompson, Jonas Paludo, Jeremy T. Larsen, Stephen M. Ansell, Thomas E. Witzig, Saurabh Zanwar, Rong He, S V Rajkumar, Taimur Sher, Shaji Kumar, Martha Q. Lacy
Publikováno v:
American Journal of Hematology. 96:945-953
Comparative data guiding initial therapy for Waldenstrom macroglobulinemia (WM), an infrequently encountered non-Hodgkin lymphoma, are sparse. We evaluated three commonly used frontline regimens: rituximab-bendamustine (R-Benda); dexamethasone, ritux
Autor:
Roberta Di Blasi, Laure Philippe, Thomas Hueso, Catherine Thieblemont, Karine Lacombe, Bénédicte Deau Fischer, Serge Bologna, Caroline Besson, Guillemette Fouquet, Sylvain Choquet, Milena Kohn, Rémy Duléry, Carole Soussain, Bernard Drenou, Pierre Feugier, Etienne Daguindau, Marc Delord, Nicolas Noel, Adrien Chauchet, Sylvain Lamure, Sandra Malak, Cédric Rossi, Bertrand Joly, Guillaume Cartron, Yassine Taoufik
Publikováno v:
American Journal of Hematology
American Journal of Hematology, Wiley, 2021, 96 (8), pp.934-944. ⟨10.1002/ajh.26209⟩
American Journal of Hematology, 2021, 96 (8), pp.934-944. ⟨10.1002/ajh.26209⟩
American Journal of Hematology, Wiley, 2021, 96 (8), pp.934-944. ⟨10.1002/ajh.26209⟩
American Journal of Hematology, 2021, 96 (8), pp.934-944. ⟨10.1002/ajh.26209⟩
International audience; Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants a
Publikováno v:
American Journal of Hematology
Nilius, Henning; Kaufmann, Jonas; Cuker, Adam; Nagler, Michael (2021). Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. American journal of hematology, 96(7), pp. 805-815. Wiley 10.1002/ajh.26194
Nilius, Henning; Kaufmann, Jonas; Cuker, Adam; Nagler, Michael (2021). Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. American journal of hematology, 96(7), pp. 805-815. Wiley 10.1002/ajh.26194
Background: The effectiveness and safety of non-heparin anticoagulants for the treatment of heparin-induced thrombocytopenia (HIT) are not fully established, and the optimal treatment strategy is unknown. In a systematic review and meta-analysis, we
Autor:
Haidar El Darsa, Sunita Ghosh, Douglas A. Stewart, Anthea Peters, Carolyn Owen, Robert Puckrin
Publikováno v:
American Journal of Hematology. 96:764-771
Central nervous system (CNS) relapse affects 5% of diffuse large B-cell lymphoma (DLBCL) patients and portends a poor prognosis. Prophylactic intravenous high-dose methotrexate (HD-MTX) is frequently employed to reduce this risk, but there is limited
Autor:
Shaji Kumar, Sarah Goldman-Mazur
Publikováno v:
American Journal of Hematology. 96:854-871
The median overall survival in multiple myeloma is rapidly approaching 10 years; however, in nearly a fifth of patients the prognosis remains poor. Therefore, the modern-day management of myeloma patients should be individualized, with more intense a
Autor:
Kiyomi Morita, Joseph D. Khoury, Marina Konopleva, Nicholas J. Short, Guillermo Garcia-Manero, Nitin Jain, Siba El Hussein, Abhishek Maiti, Hagop M. Kantarjian, Hong Fang, Farhad Ravandi, Feng Wang, Sergej Konoplev, Koji Sasaki, Koichi Takahashi, Elias Jabbour
Publikováno v:
American Journal of Hematology. 96:589-598
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is characterized by a distinct immunophenotype (CD1a-negative, CD8-negative, CD5-negative or weak-positive
Autor:
Shoshana Revel-Vilk, Michal Becker-Cohen, Barbara Rubio, Radka Stefanova Tincheva, Tama Dinur, Predrag Rodic, Beata Kieć-Wilk, Ari Zimran, Uma Ramaswami, Majdolen Istaiti, Alicia Chan, Beom Hee Lee, Chia-Feng Yang, Walla Al-Hertani, Magdalena Cerón-Rodríguez, Daniela Castillo-García, Agata Fiumara
Publikováno v:
American Journal of Hematology. 96:545-551
Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine. In 2009 it was identified as a pharmacological chaperone for mutant glucocerebrosidase, albeit in a several-fold higher dose. Unfortunately,
Publikováno v:
American Journal of Hematology
Intravenous (IV) iron is the therapy of choice when oral iron is ineffective or poorly tolerated, yet use has been limited by fears of hypersensitivity reactions (HSRs). Newer formulations that bind iron more tightly and release it more slowly have m